Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
CRNX 
Crinetics Pharmaceuticals Inc (CRNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/26/2025: CRNX (3-star) is a STRONG-BUY. BUY since 81 days. Simulated Profits (38.41%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $80.21
1 Year Target Price $80.21
| 11 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 93.66% | Avg. Invested days 58 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 12/26/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.55B USD | Price to earnings Ratio - | 1Y Target Price 80.21 |
Price to earnings Ratio - | 1Y Target Price 80.21 | ||
Volume (30-day avg) 17 | Beta 0.2 | 52 Weeks Range 24.10 - 53.55 | Updated Date 12/27/2025 |
52 Weeks Range 24.10 - 53.55 | Updated Date 12/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.53 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -99710.49% |
Management Effectiveness
Return on Assets (TTM) -28% | Return on Equity (TTM) -44.42% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3507865646 | Price to Sales(TTM) 2964.83 |
Enterprise Value 3507865646 | Price to Sales(TTM) 2964.83 | ||
Enterprise Value to Revenue 2285.25 | Enterprise Value to EBITDA -13.4 | Shares Outstanding 94891840 | Shares Floating 87690498 |
Shares Outstanding 94891840 | Shares Floating 87690498 | ||
Percent Insiders 1.99 | Percent Institutions 116.56 |
Upturn AI SWOT
Crinetics Pharmaceuticals Inc
Company Overview
History and Background
Crinetics Pharmaceuticals Inc. was founded in 2012 with the goal of developing novel therapeutics for rare endocrine disorders. The company has achieved significant milestones including the successful development and FDA approval of its lead product, Somatulineu00ae Depot (lanreotide acetate for injectable suspension), for the treatment of acromegaly and neuroendocrine tumors. Crinetics has evolved into a commercial-stage biopharmaceutical company focused on addressing unmet medical needs in endocrinology.
Core Business Areas
- Therapeutic Development and Commercialization: Crinetics focuses on the development, manufacturing, and commercialization of therapies for rare endocrine disorders. This includes the entire lifecycle from preclinical research to market access and patient support.
Leadership and Structure
Crinetics is led by a management team with extensive experience in the pharmaceutical and biotechnology industries. The company operates with a lean organizational structure, emphasizing scientific innovation and commercial execution.
Top Products and Market Share
Key Offerings
- Product Name 1: Somatulineu00ae Depot (lanreotide acetate for injectable suspension). Description: A somatostatin analog indicated for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Market Share Data: Specific market share figures for Somatuline Depot are not publicly disclosed but it is a significant player in the acromegaly and NETs treatment market. Competitors: Novartis (Signifor), Recordati (Isturisa), Pfizer (Somavert).
Market Dynamics
Industry Overview
The rare endocrine disorder market is characterized by high unmet medical needs, significant R&D investment, and a regulatory pathway that can be favorable for orphan drugs. The market is driven by advancements in diagnostics, a growing understanding of disease mechanisms, and a demand for specialized treatments.
Positioning
Crinetics is positioned as a specialized biopharmaceutical company with a strong focus on endocrinology, particularly rare diseases. Its competitive advantage lies in its deep scientific expertise in this therapeutic area and its successful commercialization of Somatulineu00ae Depot.
Total Addressable Market (TAM)
The TAM for rare endocrine disorders is substantial and growing due to increased diagnosis and improved treatment options. Crinetics is well-positioned to capture a significant portion of the market for acromegaly and GEP-NETs with its flagship product, Somatulineu00ae Depot, and is exploring opportunities in other rare endocrine conditions.
Upturn SWOT Analysis
Strengths
- Approved and commercially successful flagship product (Somatulineu00ae Depot).
- Strong scientific expertise in endocrinology.
- Established regulatory track record.
- Experienced management team.
Weaknesses
- Limited product portfolio.
- Dependence on a single major revenue-generating product.
- Significant R&D costs for pipeline development.
Opportunities
- Expansion of Somatulineu00ae Depot indications.
- Development of new therapies for other rare endocrine disorders.
- Strategic partnerships and collaborations.
- Growth in emerging markets.
Threats
- Competition from new entrants and generic drugs.
- Pricing pressures and reimbursement challenges.
- Regulatory hurdles and clinical trial failures.
- Changes in healthcare policy.
Competitors and Market Share
Key Competitors
- Novartis AG (NVS)
- Recordati S.p.A. (RECF)
- Pfizer Inc. (PFE)
Competitive Landscape
Crinetics benefits from its specialized focus on rare endocrine disorders. However, it faces competition from larger pharmaceutical companies with broader portfolios and significant resources. Its ability to innovate and effectively commercialize its products is key to maintaining its competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Crinetics has demonstrated growth driven by the successful launch and expansion of Somatulineu00ae Depot. The company has transitioned from a development-stage to a commercial-stage entity, indicating a positive historical growth trend.
Future Projections: Future projections are contingent on the success of its pipeline and market penetration of its existing products. Analyst estimates should be consulted for quantitative projections, which typically focus on revenue growth, EPS, and R&D pipeline advancements.
Recent Initiatives: Recent initiatives likely include ongoing clinical trials for pipeline candidates, efforts to expand the market reach of Somatulineu00ae Depot, and strategic business development activities.
Summary
Crinetics Pharmaceuticals Inc. is a specialized biopharmaceutical company with a strong foundation in endocrinology, anchored by its successful product, Somatulineu00ae Depot. While its focused approach offers advantages in niche markets, its reliance on a limited portfolio presents a key weakness. The company's future success hinges on its ability to navigate competitive pressures, secure regulatory approvals for new therapies, and manage R&D investments effectively to drive sustained growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company publicly available filings (e.g., SEC filings)
- Industry research reports
- Financial news and analysis websites
Disclaimers:
This JSON output is a structured representation of information about Crinetics Pharmaceuticals Inc. It is compiled from publicly available data and should not be considered financial advice. Market share and financial data are estimates and may vary. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crinetics Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-07-18 | Founder, President, CEO & Director Dr. R. Scott Struthers Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 437 | Website https://www.crinetics.com |
Full time employees 437 | Website https://www.crinetics.com | ||
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.